Detalles de la búsqueda
1.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol;
18(1): 75-87, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27908594
2.
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov;
9(2): 210-219, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30425037
3.
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.
J Thorac Oncol;
11(10): 1690-700, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-27468937
4.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Clin Cancer Res;
22(10): 2386-95, 2016 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26747242
5.
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Eur J Cancer;
50(11): 1891-9, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24857044
6.
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
J Clin Oncol;
31(35): 4453-61, 2013 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-24220555
Resultados
1 -
6
de 6
1
Próxima >
>>